PEN · Penumbra Inc
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Global embolization and access revenue | 131.1M | the second quarter of 2026 | — |
| Global thrombectomy revenue | 259M | the second quarter of 2026 | — |
| Gross profit margin | 67.9% | the second quarter of 2026 | — |
| Adjusted EBITDA non-GAAP | $266.8M | Full Year 2025 | — |
| Adjusted EBITDA margin non-GAAP | 20.5% | Q4 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PEN
this stock
Penumbra Inc
|
$12.81B | +4.6% | +17.5% | 79.9 | 4.7% |
|
ABT
Abbott Laboratories
|
$198.81B | -6.9% | +5.7% | 32.0 | 1.3% |
|
SYK
Stryker Corp
|
$126.37B | -6.3% | +11.2% | 34.1 | 2.2% |
|
MDT
Medtronic plc
|
$119.47B | -2.8% | +8.4% | 25.0 | 1.4% |
|
BSX
Boston Scientific Corp
|
$71.55B | -47.2% | +12.5% | 20.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PEN | -0.6% | +2.0% | -5.0% | +1.2% | +4.6% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +0.8% | -1.6% | -16.6% | -1.3% | -7.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.